Compare HTLD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | JANX |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 975.7M |
| IPO Year | 1995 | 2021 |
| Metric | HTLD | JANX |
|---|---|---|
| Price | $12.75 | $17.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $11.50 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 768.0K | 656.6K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $805,709,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | $182.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $12.12 |
| 52 Week High | $16.64 | $35.34 |
| Indicator | HTLD | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 67.49 |
| Support Level | $12.23 | $13.13 |
| Resistance Level | $13.92 | $30.47 |
| Average True Range (ATR) | 0.45 | 0.61 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 79.88 | 95.80 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.